Clinical Research Directory
Browse clinical research sites, groups, and studies.
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
Sponsor: Varian, a Siemens Healthineers Company
Summary
This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Official title: Daily Online Adaptive Radiation Therapy of Bladder Cancer for Reduction of Intestinal Toxicity: A Prospective Trial Using an Individualized Approach and Conventional Fractionation (ARTIA-Vesica)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2022-03-15
Completion Date
2027-03
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
Varian Ethos Adaptive Radiation Therapy
Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Locations (1)
Herlev and Gentofte Hospital
Herlev, Denmark